Imugene (ASX:IMU) obtained a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology, according to a Thursday filing with the Australian bourse.
The patent is set to expire in 2037. The technology already has intellectual property protection in the US and Japan, the filing said.
The clinical-stage immuno-oncology company's shares rose 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.